13
Participants
Start Date
February 28, 2009
Primary Completion Date
February 28, 2011
Study Completion Date
February 28, 2011
Xolair injections
In addition to Advair Diskus 250/50 or 500/50, subjects will receive 150 to 375 mg subcutaneous injection every 2 or 4 weeks (depending on IgE levels) for 16 weeks.
UCLA, Los Angeles
Collaborators (2)
Novartis
INDUSTRY
Genentech, Inc.
INDUSTRY
University of California, Los Angeles
OTHER